About: Marketing authorisation

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Marketing authorisation Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/c/3Twp61YyMd

Marketing authorisation is the process of reviewing and assessing the evidence to support a medicinal product, such as a drug, in relation to its marketing, finalised by granting of a licence to be sold. This process is performed within a legal framework defining the requirements necessary for successful application to the regulatory authority, details on the assessment procedure (based on quality, efficacy and safety criteria), and also the circumstances where a marketing authorisation already granted may be withdrawn, suspended or revoked.

Attributes	Values
rdfs:label	Marketing authorisation (en)
rdfs:comment	Marketing authorisation is the process of reviewing and assessing the evidence to support a medicinal product, such as a drug, in relation to its marketing, finalised by granting of a licence to be sold. This process is performed within a legal framework defining the requirements necessary for successful application to the regulatory authority, details on the assessment procedure (based on quality, efficacy and safety criteria), and also the circumstances where a marketing authorisation already granted may be withdrawn, suspended or revoked. (en)
dct:subject	Pharmaceuticals policy Pharmaceutical industry
Wikipage page ID	27598596 (xsd:integer)
Wikipage revision ID	1083650586 (xsd:integer)
Link from a Wikipage to another Wikipage	New Drug Application Electronic Common Technical Document Radionuclide generator Common Technical Document Pharmaceuticals policy Pharmaceutical industry Marketing Authorization Application
Link from a Wikipage to an external page	https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation
sameAs	Marketing authorisation Marketing authorisation Marketing authorisation
dbp:wikiPageUsesTemplate	dbt:More_citations_needed dbt:When
has abstract	Marketing authorisation is the process of reviewing and assessing the evidence to support a medicinal product, such as a drug, in relation to its marketing, finalised by granting of a licence to be sold. This process is performed within a legal framework defining the requirements necessary for successful application to the regulatory authority, details on the assessment procedure (based on quality, efficacy and safety criteria), and also the circumstances where a marketing authorisation already granted may be withdrawn, suspended or revoked. The application dossier for marketing authorisation is called a New Drug Application (NDA) in the USA or Marketing Authorisation Application (MAA) in the European Union and other countries, or simply registration dossier. This contains data proving that the drug has quality, efficacy and safety properties suitable for the intended use, additional administrative documents, samples of finished product or related substances and reagents necessary to perform analyses of finished product as described in that dossier. The content and format of the dossier must follow rules as defined by the regulator. For example, since 2003, the authorities in the United States, the European Union and Japan ask for the Common Technical Document (CTD) format, and more recently, its electronic version – the electronic Common Technical Document (eCTD). The application is filed with the regulator, which can be either an independent regulatory body or a specialised department in the ministry of health. Depending on jurisdiction, the resulting document may be more detailed (in addition to data identifying the product and its marketing authorisation holder), for example containing addresses of all manufacturing sites, appended labelling, artwork of packaging components, etc. or may be simplified to a one-page document called certificate of registration (and containing minimal data identifying the product and its source). (en)
prov:wasDerivedFrom	wikipedia-en:Marketing_authorisation?oldid=1083650586&ns=0
page length (characters) of wiki page	6432 (xsd:nonNegativeInteger)
foaf:isPrimaryTopicOf	wikipedia-en:Marketing_authorisation
is Link from a Wikipage to another Wikipage of	Pfizer–BioNTech COVID-19 vaccine Risdiplam Pharmacy and Poisons Board Marketing Authorisation Application Alipogene tiparvovec European Directorate for the Quality of Medicines & HealthCare Test data exclusivity Janssen COVID-19 vaccine Association of the British Pharmaceutical Industry Marketing authorization Ibritumomab tiuxetan National Agency of Drug and Food Control Radioimmunotherapy MA Off-label use Official Medicines Control Laboratory Phage therapy Peptide receptor radionuclide therapy Market approval Marketing approval
is Wikipage redirect of	Marketing authorization Market approval Marketing approval
is Wikipage disambiguates of	MA
is foaf:primaryTopic of	wikipedia-en:Marketing_authorisation

Faceted Search & Find service v1.17_git147 as of Sep 06 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3332 as of Dec 5 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 56 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software